Induction immunosuppression with anti-T lymphocyte globulin (GrafalonR) demonstrates low rates of EB viremia (EBV) and PTLD, and excellent graft survival and rejection profiles in pediatric kidney transplant recipients

Simulect (basiliximab) - Novartis

Marwa Mohamed1,2; Abdalazeez AlGhraizat1; Waldo Concepcion1,3,4; Martin Bitzan1,3

Sep 17, 2026